MoneyWeek’s comprehensive guide to this week’s share tips
Oct 29, 2021
2 minutes
Three to buy
Indivior
The Sunday Times
n 2019 Indivior was charged in the US with running an “illicit nationwide scheme to increase prescriptions” of a version of its opioid-addiction treatment. But the drugmaker seems to have redeemed itself. It has invested in a new treatment for cannabis-related disorders, branched out into alcohol-misuse drugs and grown sales of its injection for opioid addiction. But the stock is still selling for half its 2018 price. Sales
You’re reading a preview, subscribe to read more.
Start your free 30 days